University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Factors associated with health status and exacerbations in COPD maintenance therapy with dry powder inhalers

Simple item page
dc.contributor.authorW. H. Kocks, Janwillem
dc.contributor.authorWouters, Hans
dc.contributor.authorBosnic-Anticevich, Sinthia
dc.contributor.authorvan Cooten, Joyce
dc.contributor.authorCorreia de Sousa, Jaime
dc.contributor.authorCvetkovski, Biljana
dc.contributor.authorDekhuijzen, Richard
dc.contributor.authorDijk, Lars
dc.contributor.authorDvortsin, Evgeni
dc.contributor.authorGarcia Pardo, Marina
dc.contributor.authorGardev, Asparuh
dc.contributor.authorGawlik, Radosław
dc.contributor.authorvan Geer - Postmus, Iris
dc.contributor.authorvan der Ham, Iris
dc.contributor.authorHarbers, Marten
dc.contributor.authorde la Hoz, Alberto
dc.contributor.authorJanse, Ymke
dc.contributor.authorKerkhof, Marjan
dc.contributor.authorLavorini, Federico
dc.contributor.authorMaricoto, Tiago
dc.contributor.authorMeijer, Jiska
dc.contributor.authorMetz, Boyd
dc.contributor.authorPrice, David
dc.contributor.authorRoman-Rodriguez, Miguel
dc.contributor.authorSchuttel, Kirsten
dc.contributor.authorStoker, Nilouq
dc.contributor.authorTsiligianni, Ioanna
dc.contributor.authorUsmani, Omar
dc.contributor.authorLeving, Marika T.
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.date.accessioned2022-10-26T09:44:01Z
dc.date.available2022-10-26T09:44:01Z
dc.date.issued2022-05-26
dc.descriptionFunding Information: J.K. reports grants, personal fees and non-financial support from AstraZeneca, GSK and Boehringer Ingelheim; grants and personal fees from Chiesi Pharmaceuticals and TEVA; grants from Mundipharma; personal fees from MSD and COVIS Pharma; and also holds 72.5% of shares in the General Practitioners Research Institute. H.W. has received grants from Boehringer Ingelheim, which is the financial and scientific partner of GPRI for the submitted study, and from AstraZeneca, Novartis and Chiesi for scientific projects in the area of COPD/asthma. S.B.-A. has received grants from TEVA, and personal fees from TEVA, Boehringer Ingelheim, AstraZeneca, GSK, Sanofi and Mylan. J.C.d.S. reports or personal fees from AstraZeneca, Bial, Boehringer Ingelheim, GSK, Medinfar, Mundipharma and Sanofi. B.C. received honorarium from GSK and Sanofi. J.v.C., L.D., I.v.G.-P., I.v.d.H., Y.J., M.K., B.M., K.S., N.S., M.H., B.M. and M.T.L. were employed by General Practitioners Research Institute (GPRI) at the time of the study. In the past three years (2019–2021), GPRI conducted investigator- and sponsor-initiated research funded by non-commercial organizations, academic institutes, and pharmaceutical companies (including AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mundipharma, Novartis, and Teva). R.D. has received grants and personal fees from TEVA, Boehringer Ingelheim, AstraZeneca, GSK, Chiesi, Focus Care, and Glenmark. R.G. has received personal fees from AstraZeneca, GSK and Chiesi. E.D. holds 27.5% of shares in the General Practitioners Research Institute. M.G.P. receives grants from AstraZeneca, GSK and Boehringer Ingelheim. A.G. and A.d.l.H. are employees of Boehringer Ingelheim. F.L. received grants and personal fees from GSK, personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Menarini International, Novartis, Orion, and Trudell International, outside the submitted work. T.M. is an Assoicate Editor at npj Primary Care Respiratory Medicine. J.M. received grants from Boehringer Ingelheim, during the conduct of the study; and grants from AstraZeneca, Chiesi, Novartis, and GSK, outside the submitted work. D.P. reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Theravance and Zentiva (Sanofi Generics); grants from the British Lung Foundation, Respiratory Effectiveness Group, UK National Health Service, and AKL Research and Development Ltd; personal fees from Cipla, GlaxoSmithKline, Kyorin, Merck, Mundipharma, Airway Vista Secretariat, EPG Communication Holdings Ltd, FIECON Ltd, Fieldwork International, OM Pharma SA, PeerVoice, Phadia AB, Spirosure Inc, Strategic North Limited, Synapse Research Management Partners S.L., Talos Health Solutions, and WebMD Global LLC; non-financial support from Efficacy and Mechanism Evaluation programme and Health Technology Assessment; stock/stock options from AKL Research and Development Ltd, which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 92.61% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and 5% shareholding in Timestamp, which develops adherence monitoring technology. M.R.-R. receives grants and personal fees from AstraZeneca and GSK; and personal fees from Boehringer Ingelheim, Chiesi, Menarini, Mundipharma, Novartis, Pfizer, TEVA and BIAL. I.T. reports grants and personal fees from GSK, AstraZeneca, Boehringer Ingelheim, Menarini, Novartis, Chiesi and Elpen. O.U. reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Edmond Pharma, Chiesi and GSK; grants from Edmond Pharma; and personal fees from Napp, Mundipharma, Sandoz, Takeda, Cipla, COVIS, Novartis, Mereobiopharma, Orion, and Menarini. S.B.-A. and T.M. are Associate Editors at npj Primary Care Respiratory Medicine, and I.T. is Editor in Chief. These authors were not involved in the journal’s review of, or decisions related to, this manuscript.en
dc.description.statusPeer revieweden
dc.format.extent10
dc.format.extent1762830
dc.identifier220028501
dc.identifier23be7906-0d38-4b17-90c1-ed7b5a90572b
dc.identifier85130698707
dc.identifier35618739
dc.identifier.citationW. H. Kocks, J, Wouters, H, Bosnic-Anticevich, S, van Cooten, J, Correia de Sousa, J, Cvetkovski, B, Dekhuijzen, R, Dijk, L, Dvortsin, E, Garcia Pardo, M, Gardev, A, Gawlik, R, van Geer - Postmus, I, van der Ham, I, Harbers, M, de la Hoz, A, Janse, Y, Kerkhof, M, Lavorini, F, Maricoto, T, Meijer, J, Metz, B, Price, D, Roman-Rodriguez, M, Schuttel, K, Stoker, N, Tsiligianni, I, Usmani, O & Leving, M T 2022, 'Factors associated with health status and exacerbations in COPD maintenance therapy with dry powder inhalers', npj Primary Care Respiratory Medicine, vol. 32, no. 1, 18. https://doi.org/10.1038/s41533-022-00282-yen
dc.identifier.doi10.1038/s41533-022-00282-y
dc.identifier.iss1en
dc.identifier.issn2055-1010
dc.identifier.urihttps://hdl.handle.net/2164/19433
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85130698707&partnerID=8YFLogxKen
dc.identifier.vol32en
dc.language.isoeng
dc.relation.ispartofnpj Primary Care Respiratory Medicineen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectR Medicineen
dc.subjectPulmonary and Respiratory Medicineen
dc.subjectPublic Health, Environmental and Occupational Healthen
dc.subjectFamily Practiceen
dc.subjectSupplementary Informationen
dc.subject.lccRen
dc.titleFactors associated with health status and exacerbations in COPD maintenance therapy with dry powder inhalersen
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Kocks_etal_NPJ_Factors_associated_with_VOR.pdf
Size:
1.68 MB
Format:
Adobe Portable Document Format
Download

Collections

All research